Brokerages Set aTyr Pharma, Inc. (NASDAQ:ATYR) PT at $17.00

aTyr Pharma, Inc. (NASDAQ:ATYR) has been assigned an average rating of “Hold” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.00.

ATYR has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings upgraded shares of aTyr Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Freedom Capital raised shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th.

aTyr Pharma Stock Down 0.6%

aTyr Pharma stock opened at $0.48 on Tuesday. The stock has a market cap of $47.06 million, a PE ratio of -0.66 and a beta of 0.52. aTyr Pharma has a 12-month low of $0.40 and a 12-month high of $6.50. The business’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.71.

aTyr Pharma (NASDAQ:ATYR) last posted its earnings results on Friday, May 15th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. As a group, analysts expect that aTyr Pharma will post -0.66 earnings per share for the current year.

Insider Activity at aTyr Pharma

In other news, Director Paul Schimmel purchased 100,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was bought at an average cost of $0.50 per share, for a total transaction of $50,000.00. Following the purchase, the director owned 779,143 shares of the company’s stock, valued at approximately $389,571.50. The trade was a 14.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.75% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of ATYR. California State Teachers Retirement System bought a new position in aTyr Pharma in the second quarter valued at about $28,000. Renaissance Technologies LLC acquired a new stake in shares of aTyr Pharma during the first quarter valued at about $32,000. ADAR1 Capital Management LLC grew its holdings in shares of aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after purchasing an additional 13,385 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of aTyr Pharma during the fourth quarter worth about $41,000. Finally, Legal & General Group Plc acquired a new position in shares of aTyr Pharma in the second quarter valued at approximately $49,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.